Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial

Simple item page
dc.contributor.authorDorman, Klara
dc.contributor.authorBoeck, Stefan
dc.contributor.authorCaca, Karel
dc.contributor.authorReichert, Maximilian
dc.contributor.authorEttrich, Thomas J.
dc.contributor.authorOettle, Helmut
dc.contributor.authorWaidmann, Oliver
dc.contributor.authorModest, Dominik P.
dc.contributor.authorMüller, Lothar
dc.contributor.authorMichl, Patrick
dc.contributor.authorKanzler, Stephan
dc.contributor.authorPink, Daniel
dc.contributor.authorReinacher-Schick, Anke
dc.contributor.authorGeissler, Michael
dc.contributor.authorPelz, Henning
dc.contributor.authorKunzmann, Volker
dc.contributor.authorHeld, Swantje
dc.contributor.authorSchichtl, Thomas
dc.contributor.authorHeinemann, Volker
dc.contributor.authorKullmann, Frank
dc.date.accessioned2025-12-10T13:01:20Z
dc.date.available2025-12-10T13:01:20Z
dc.date.issued2024
dc.identifier.doiExternal10.1016/s2468-1253(24)00197-3
dc.identifier.urlhttps://oparu.uni-ulm.de/handle/123456789/58843
dc.language.isoen
dc.publisherUniversität Ulm
dc.subject.ddcDDC 610 / Medicine & health
dc.titleAlternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
dc.typeWissenschaftlicher Artikel
source.fromPage935
source.identifier.eissn2468-1253
source.issue10
source.publisherElsevier
source.titleThe Lancet Gastroenterology & Hepatology
source.toPage943
source.volume9
source.year2024
uulm.affiliationSpecificUKU. Klinik für Innere Medizin I
uulm.categoryPublikationsnachweise
uulm.identifier.pubmed39159648
uulm.identifier.wos1309365200001
uulm.typeDCMIText

Files

Collections

Publikationsnachweise